Pharmaceuticals

Novo Nordisk Merck & Co Inc Eli Lilly Novartis Pfizer GSK Vaccine Development Amylyx Pharmaceuticals AbbVie Merck & Co. Merck AstraZeneca Drug Sales BioSyent Inc. Sanofi

3 ARTICLES

5d ago

GSK Reports Strong Q1 Results, Confirms Readiness for Potential US Pharma Tariffs

The company surpassed analyst expectations, reaffirmed 2025 guidance, and outlined strategies to mitigate tariff impacts while navigating mixed portfolio performance.

3 ARTICLES

last wk.

AbbVie Raises 2025 Profit Forecast Following Strong Q1 Growth in Immunology Drugs

3 ARTICLES

2mo ago

Novavax Reports Narrower Q4 Loss and Strategic Shift Away from COVID-19 Vaccine Commercialization

8 ARTICLES

2mo ago

AbbVie Reports Strong Sales Growth for Skyrizi and Rinvoq, Boosts 2027 Revenue Outlook

19 ARTICLES

5mo ago

Novo Nordisk Expands Wegovy Supply Amid Compounding Drug Concerns

4 ARTICLES

6mo ago

Merck's Q3 Earnings Exceed Expectations Despite Gardasil Sales Slump in China

6 ARTICLES

6mo ago

Next Surpasses £1 Billion Profit Milestone Amid Strong Autumn Sales

6 ARTICLES

6mo ago

Pfizer's Strong Q3 Earnings Challenge Activist Investor's Push for Change

Pharmaceuticals

GSK Reports Strong Q1 Results, Confirms Readiness for Potential US Pharma Tariffs

AbbVie Raises 2025 Profit Forecast Following Strong Q1 Growth in Immunology Drugs

Novavax Reports Narrower Q4 Loss and Strategic Shift Away from COVID-19 Vaccine Commercialization

Eli Lilly Reports Mixed Q4 Results as Key Drug Sales Fall Short of Expectations

AstraZeneca Reports Strong 2024 Results While Facing China Tax Probe

Merck Stock Declines After Weak 2025 Guidance Despite Strong Q4 Results

Merck Cuts 2025 Revenue Forecast After Halting Gardasil Shipments to China

AbbVie Reports Strong Sales Growth for Skyrizi and Rinvoq, Boosts 2027 Revenue Outlook

Novo Nordisk Expands Wegovy Supply Amid Compounding Drug Concerns

Merck's Q3 Earnings Exceed Expectations Despite Gardasil Sales Slump in China

Next Surpasses £1 Billion Profit Milestone Amid Strong Autumn Sales

Pfizer's Strong Q3 Earnings Challenge Activist Investor's Push for Change